Associated Papers
Lack of Association of Generic Brittle Status with Genetics and Physiologic Measures in Patients with Epilepsy.
Das S et al.
Pharmaceutical Research, 2020
Fexofenadine, a Putative In Vivo P-glycoprotein Probe, Fails to Predict Clearance of the Substrate Tacrolimus in Renal Recipients.
Vanhove T et al.
Clinical Pharmacology and Therapeutics, 2017
Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
Ogasawara K et al.
Clinical Pharmacokinetics, 2013
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Bosch TM et al.
Molecular Diagnosis & Therapy, 2006
Select a paper to view details